Contribute Try STAT+ Today

Good morning, everyone, and welcome to the middle of the week. You made it this far, so why not proceed. After all, consider the alternatives. Not pretty, yes? While you do so, we will brew another cup of stimulation — maple bourbon is the latest obsession — and forage for some tidbits. So time to get cracking. We hope your day is manageable, despite the new world in which we live, and that you remain healthy. And as always, do keep in touch.

Scientists trying to develop treatments for the new coronavirus have struggled to get a hold of blood samples from recovered patients, which are needed because these contain the building blocks for creating new medicines, The Wall Street Journal writes. More than 180,000 people globally have been infected by the new coronavirus, but blood samples from recovered patients have been in short supply. The challenges researchers face in obtaining samples illustrate the hurdles involved in rapidly developing drugs for a new, poorly understood virus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.